Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04962347 · ClinicalTrials.gov registry record
Real World Study of COVID-19 in a Flyover Region
A clinical trial of COVID-19, sponsored by Tulane University.
- Completed
- Registry status
- 1,800
- Enrollment target
- 1
- Study location
NCT04962347: Completed study of COVID-19, sponsored by Tulane University.
NCT04962347 is a study of COVID-19 that has completed, run by Tulane University. The registered enrollment target is 1,800 participants, below the 38,459-participant average among 298 other COVID-19 trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04962347, a study of COVID-19, has completed, sponsored by Tulane University.
- COMPLETED
- Registry status
- 1,800 participants
- Enrollment target
- 1
- Study location
Study Summary
Real world data are needed on remdesivir (RDV) efficacy in COVID-19, especially in the underserved populations of the United States (U.S.) Gulf Coast as initial clinical trials may not be representative of this population. Specifically, regions such as New Orleans are 60% African American, a much greater proportion of African Americans than initial RDV studies. The main hypothesis is that a real world data based study will provide specific information related to RDV efficacy in COVID-19 patients from underserved / underrepresented populations of the U.S. Gulf Coast. The main goal of this study is to provide population-centered information related on RDV related to indication (stage of disease), dosing, monitoring, efficacy and contraindications for future COVID-19 patients in this underserved region.
Primary Outcome
Clinical severity will be measured using 7-point ordinal scale (1 Death, 2 Hospitalized, on invasive mechanical ventilation or Extracorporeal membrane oxygenation (ECMO), 3 Hospitalized, on non-invasive ventilation or high flow oxygen devices, 4 Hospitalized, requiring low flow supplemental oxygen (less than 15L), 5 Hospitalized, not requiring supplemental oxygen-requiring ongoing medical care (COVID-19 related or otherwise), 6 Hospitalized, not requiring oxygen-no longer requires ongoing medica
Conditions Studied
Study Locations (1)
Louisiana
- Tulane University Medical Center - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2021-10-14 |
| Est. Completion | 2022-10-18 |
What the finished NCT04962347 record still lists
NCT04962347 is an observational study that tracks outcomes without assigning an intervention. Its 1,800 participants enrollment target places it among the larger protocols in the corpus, below the 38,459-participant average among 298 other COVID-19 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 0 interventions.
NCT04962347 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT04962347 about?
NCT04962347 is a clinical study titled "Real World Study of COVID-19 in a Flyover Region". Real world data are needed on remdesivir (RDV) efficacy in COVID-19, especially in the underserved populations of the United States (U.S.) Gulf Coast as initial clinical trials may not be representative of this population. Specifically, regions such as New Orleans are 60% African American, a much gr...
What is the current status of trial NCT04962347?
This trial is currently completed. The enrollment target is 1,800 participants. The study started on 2021-10-14. Estimated completion is 2022-10-18.
What conditions does trial NCT04962347 study?
This clinical trial studies the following conditions: COVID-19.
Who is sponsoring clinical trial NCT04962347?
This trial is sponsored by Tulane University, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04962347 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04962347's enrollment target sits among peer trials
1,800 48th of 298 higher than 251 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
- NCT04980794 · 1,800 participants · NA
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
- NCT05258656 · 1,800 participants · NA
Childhood Activities Nutrition and Development Oversight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI